A crystalline form i of a benzodiazepine derivative and a process for its preparation
By optimizing the preparation method, a benzodiazepine derivative crystal form I with good solubility and stability was prepared, which solved the problem of poor solubility and stability in the existing technology and realized efficient and low-cost large-scale production.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- CHENGDU EASTON BIOPHARMACEUTICALS CO LTD
- Filing Date
- 2026-01-15
- Publication Date
- 2026-07-17
AI Technical Summary
In the prior art, different crystal forms of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5-methyl-4,5-dihydro-imidazo[1,5-α][1,4]benzodiazepine-6-one exhibit differences in solubility and stability in the pharmaceutical field, lacking effective preparation methods and making it difficult to achieve large-scale production.
A crystalline form I of a benzodiazepine derivative and its preparation method are provided. By controlling the specific ratio of solvent and seed crystals and the dropping temperature, crystalline form I with good solubility, stability and bioavailability can be prepared. The method is simple, reproducible, uses little solvent and is easy to recover, and is suitable for large-scale production.
This study achieved high yield, stability, and bioavailability of benzodiazepine derivative crystal form I, reduced reagent costs, simplified the operation process, made it suitable for large-scale production, and improved the solubility and stability of the drug.
Smart Images
Figure CN122404337A_ABST